Pfizer Limited (BOM:500680)
India
· Delayed Price · Currency is INR | Market Cap | 233.40B |
| Revenue (ttm) | 22.81B |
| Net Income (ttm) | 7.68B |
| Shares Out | n/a |
| EPS (ttm) | 167.79 |
| PE Ratio | 30.41 |
| Forward PE | 34.23 |
| Dividend | 165.00 (3.27%) |
| Ex-Dividend Date | Jul 9, 2025 |
| Volume | 519 |
| Average Volume | 1,252 |
| Open | 5,146.95 |
| Previous Close | 5,087.05 |
| Day's Range | 5,062.60 - 5,147.60 |
| 52-Week Range | 3,742.90 - 6,452.85 |
| Beta | n/a |
| RSI | 41.54 |
| Earnings Date | Aug 14, 2025 |
About Pfizer
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a netwo... [Read more]
Financial Performance
In 2024, Pfizer's revenue was 22.81 billion, an increase of 4.02% compared to the previous year's 21.93 billion. Earnings were 7.68 billion, an increase of 39.23%.
Financial StatementsNews
Pfizer shares jump over 2% after launch of next-gen 20-valent pneumococcal vaccine in India
Shares of Pfizer Limited rose 2.07% to Rs 5,165.50 on Tuesday, August 12, following the company’s announcement of the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vacc...